{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:18:35Z","timestamp":1791497915191,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":54,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jbc.2021.100470","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T21:56:06Z","timestamp":1614203766000},"page":"100470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus"],"prefix":"10.1016","volume":"296","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8578-8551","authenticated-orcid":false,"given":"Einat B.","family":"Vitner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0664-8628","authenticated-orcid":false,"given":"Hagit","family":"Achdout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Avraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boaz","family":"Politi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilach","family":"Cherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadas","family":"Tamir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yfat","family":"Yahalom-Ronen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Paran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Melamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam","family":"Erez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer","family":"Israely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2021.100470_bib1","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrmicro975","article-title":"Antivirals and antiviral strategies","volume":"2","author":"Clercq","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jbc.2021.100470_bib2","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2021.100470_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12974-016-0570-2","article-title":"Induction of the type I interferon response in neurological forms of Gaucher disease","volume":"13","author":"Vitner","year":"2016","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.jbc.2021.100470_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164377","article-title":"A\u00a0lipidomics approach in the characterization of Zika-infected mosquito cells: Potential targets for breaking the transmission cycle","volume":"11","author":"Melo","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2021.100470_bib5","doi-asserted-by":"crossref","first-page":"12276","DOI":"10.1128\/JVI.00970-14","article-title":"Modulation of hepatitis C virus genome replication by glycosphingolipids and four-phosphate adaptor protein 2","volume":"88","author":"Khan","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.jbc.2021.100470_bib6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.celrep.2016.05.070","article-title":"Cytomegalovirus restructures lipid rafts via a US28\/CDC42-mediated pathway, enhancing cholesterol efflux from host cells","volume":"16","author":"Low","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.jbc.2021.100470_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006853","article-title":"Dynamic remodeling of lipids coincides with dengue virus replication in the midgut of Aedes aegypti mosquitoes","volume":"14","author":"Chotiwan","year":"2018","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jbc.2021.100470_bib8","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1194\/jlr.M049148","article-title":"Lipidomics identifies a requirement for peroxisomal function during influenza virus replication","volume":"55","author":"Tanner","year":"2014","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.jbc.2021.100470_bib9","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1128\/JVI.00870-08","article-title":"Influenza virus infection augments NK cell inhibition through reorganization of major histocompatibility complex class I proteins","volume":"82","author":"Achdout","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.jbc.2021.100470_bib10","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1248\/bpb.29.1575","article-title":"Suppression of the biosynthesis of cellular sphingolipids results in the inhibition of the maturation of influenza virus particles in MDCK cells","volume":"29","author":"Hidari","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jbc.2021.100470_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00017-19","article-title":"Glucosylceramidase maintains influenza virus infection by regulating endocytosis","volume":"93","author":"Drews","year":"2019","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.jbc.2021.100470_bib12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s12325-016-0474-7","article-title":"Modulation of neuroinflammation in the central nervous system: Role of chemokines and sphingolipids","volume":"34","author":"Gualtierotti","year":"2017","journal-title":"Adv. Ther."},{"key":"10.1016\/j.jbc.2021.100470_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature13476","article-title":"Sphingolipid lysosomal storage disorders","volume":"510","author":"Platt","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jbc.2021.100470_bib14","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/ijms17071065","article-title":"Less is more: Substrate reduction therapy for lysosomal storage disorders","volume":"17","author":"Coutinho","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbc.2021.100470_bib15","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2337\/db06-0719","article-title":"Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes","volume":"56","author":"Zhao","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.jbc.2021.100470_bib16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.jbc.2021.100470_bib17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jbc.2021.100470_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043310","article-title":"Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease","volume":"7","author":"Cabrera-Salazar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2021.100470_bib19","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760200342","article-title":"SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network","volume":"115","author":"Araujo","year":"2020","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.jbc.2021.100470_bib20","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1099\/jgv.0.001453","article-title":"SARS-coronavirus-2 replication in Vero E6 cells: Replication kinetics, rapid adaptation and cytopathology","volume":"101","author":"Ogando","year":"2020","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.jbc.2021.100470_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228735","article-title":"Glucosylceramide synthase maintains influenza virus entry and infection","volume":"15","author":"Drews","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2021.100470_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006316","article-title":"A\u00a0role for glycolipid biosynthesis in severe fever with thrombocytopenia syndrome virus entry","volume":"13","author":"Drake","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jbc.2021.100470_bib23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.tim.2010.04.003","article-title":"Targeting a host process as an antiviral approach against dengue virus","volume":"18","author":"Sayce","year":"2010","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.jbc.2021.100470_bib24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/JVI.74.1.564-572.2000","article-title":"Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum","volume":"74","author":"Courageot","year":"2000","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.jbc.2021.100470_bib25","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1021\/jm300171v","article-title":"Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection","volume":"55","author":"Yu","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jbc.2021.100470_bib26","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1073\/pnas.94.5.1822","article-title":"Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: Evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion","volume":"94","author":"Mehta","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2021.100470_bib27","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1053\/jhep.2001.25103","article-title":"Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: Therapeutic implications","volume":"33","author":"Mehta","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jbc.2021.100470_bib28","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1128\/AAC.01319-10","article-title":"Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release","volume":"55","author":"Qu","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jbc.2021.100470_bib29","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1097\/QAD.0b013e32830efd96","article-title":"N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery","volume":"22","author":"Pollock","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.jbc.2021.100470_bib30","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1128\/jvi.70.10.7153-7160.1996","article-title":"N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure","volume":"70","author":"Fischer","year":"1996","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.jbc.2021.100470_bib31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/jac\/dku349","article-title":"Strain-specific antiviral activity of iminosugars against human influenza A viruses","volume":"70","author":"Hussain","year":"2015","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.jbc.2021.100470_bib32","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1128\/AAC.01554-12","article-title":"Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in\u00a0vivo","volume":"56","author":"Miller","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jbc.2021.100470_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004524","article-title":"Iminosugars inhibit dengue virus production via inhibition of ER alpha-glucosidases--not glycolipid processing enzymes","volume":"10","author":"Sayce","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.jbc.2021.100470_bib34","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1016\/S0021-9258(17)37202-2","article-title":"N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis","volume":"269","author":"Platt","year":"1994","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2021.100470_bib35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/978-3-7091-1511-4_20","article-title":"Neuronal forms of Gaucher disease","author":"Vitner","year":"2013","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jbc.2021.100470_bib36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A\u00a0specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease","volume":"91","author":"McEachern","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jbc.2021.100470_bib37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","article-title":"ELIGLUSTAT TARTRATE: Glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease","volume":"35","author":"Shayman","year":"2010","journal-title":"Drugs Future"},{"key":"10.1016\/j.jbc.2021.100470_bib38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","article-title":"Challenges and opportunities with drug repurposing: Finding strategies to find alternative uses of therapeutics","volume":"15","author":"Talevi","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.jbc.2021.100470_bib39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/jama.2015.459","article-title":"Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: The ENGAGE randomized clinical trial","volume":"313","author":"Mistry","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jbc.2021.100470_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","article-title":"Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe","volume":"37","author":"Belmatoug","year":"2017","journal-title":"Eur. J. Intern. Med."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002192582100243X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002192582100243X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:45:36Z","timestamp":1634431536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002192582100243X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":40,"alternative-id":["S002192582100243X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2021.100470","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2021.100470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100470"}}